Navigation Links
The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma
Date:2/22/2011

THOUSAND OAKS, Calif., Feb. 22, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced the publication of results from a pivotal Phase 3 study of 1,776 advanced cancer patients with different types of solid tumors (not including breast and prostate cancer) or multiple myeloma, which compared XGEVA(denosumab) to Zometa® (zoledronic acid) in preventing skeletal-related events (SREs). The study, which appeared today in the Journal of Clinical Oncology, found that XGEVA was non-inferior to Zometa in delaying or preventing SREs.

"Almost every type of cancer has the potential to spread to the bone, putting patients at risk for devastating bone complications, like fracture or compression of the spinal cord," said David H. Henry, M.D., clinical professor of medicine, Pennsylvania Hospital, Philadelphia, PA. "Once a patient has bone metastases one of our major goals is to prevent events like fracture or spinal cord compression. XGEVA is an important new option to help prevent these debilitating complications."

XGEVA, the first and only RANK Ligand inhibitor indicated for the prevention of SREs in patients with bone metastases from solid tumors was approved by the U.S. Food and Drug Administration (FDA) on Nov. 18, 2010.  The approval was based in part on results described in this publication. XGEVA is not indicated for the prevention of SREs in patients with multiple myeloma.

Key Study ResultsFor the primary endpoint of this study, the median time to first on-study SRE (defined as fracture, radiation to bone, surgery to bone, or spinal cord compression) was 20.6 months for patients receiving XGEVA and 16.3 months for patients receiving Zometa (hazard ratio 0.84, 95 percent CI: 0.71-0.98), which is statistically significant for non-inferiority (p=0.0007). Although numerically greater, the delay in the time to first SRE associated wi
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
2. Adlyfe Study on the Detection of Misfolded Proteins Published in the Journal Transfusion
3. Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
4. Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in New England Journal of Medicine
5. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
6. Vaccine Study in New England Journal of Medicine Wrong in Concluding Mercury Exposures are Harmless, States SafeMinds
7. Risks Associated With Face Transplants May Be Lower Than Previously Thought, ASPS Journal Review Suggests
8. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
9. Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
10. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
11. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... STUTTGART , Alemania, December 17, 2014 ... del año anterior, con un alto nivel de gasto ... pasado año fiscal 2013/14 (finalizado el 30 de septiembre ... por ciento a 4.287 millones de euros (año anterior: ... de la moneda desfavorables. Las ganancias (EBIT) crecieron un ...
(Date:12/17/2014)... Dec. 17, 2014 With advancements in ... MRI market is seeing new growth, according to ... scans account for the majority of market volume, ... of images, which are creating opportunities for more sophisticated ... is growing at a rate of 4%, with ...
(Date:12/17/2014)...  IGI Laboratories, Inc. (NYSE MKT: IG; "IGI" or ... of $125 million aggregate principal amount of 3.75% Convertible ... offered and sold only to qualified institutional buyers pursuant ... as amended (the "Securities Act"). The Notes ... year, payable semiannually in arrears on June 15 and ...
Breaking Medicine Technology:ZEISS confirma su posición en un entorno difícil 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4
... March 5, 2012  RoundTable Healthcare Partners ("RoundTable"), an ... healthcare industry, announced today that Kent J. Davies ... RoundTable III Platform Development Corporation ("RPDC"), a Fund ... focus his attention on the identification and development ...
... -- Database101.com, a leading provider of email marketing, ... businesses and salespeople, will now offer its mailing lists and ... for marketers and salespeople. "Many marketers and small ... finding new ways to market successfully" said Vin Gupta, founder ...
Cached Medicine Technology:RoundTable Healthcare Partners Names Kent J. Davies CEO of Newly Formed Platform Development Corporation 2Database101.com Offers Hot Sales Leads & Email Lists, ONLINE, with NO Minimum Order! 2
(Date:12/20/2014)... December 20, 2014 Weddingshe.com has recently ... launched a site-wide promotion of special occasion dresses for ... popular supplier of special occasion dresses for global women. ... with big discounts, up to 80% off. Among the ... Sequins Short Sweet 16 Dress) is very popular. What’s ...
(Date:12/20/2014)... December 20, 2014 DePuy Pinnacle ... metal-on-metal version of the artificial hip system was ... and federal courts, Bernstein Liebhard LLP reports. According ... County Superior Court on December 2nd, counsel in ... deposition of plaintiffs on November 19, 2014, with ...
(Date:12/20/2014)... Recently, VogueQueen.com, a leading wedding dress wholesaler and retailer, ... for 2015. Great discounts are now offered on all ... get a discount, up to 80% off, when they ... 30, 2015. , VogueQueen.com has recently released its new ... promotion. Many customers worldwide like VogueQueen’s special designs which ...
(Date:12/20/2014)... New York, New York (PRWEB) December 20, 2014 ... ) continue to move forward in U.S. ... a new study which suggests that children treated ... prolactin, a hormone linked to breast development and ... Psychopharmacology, looked at 34 children and adolescents who ...
(Date:12/20/2014)... 2014 Recently, AngelWeddingDress.com has introduced its ... for the coming Christmas. In the promotion, all buyers ... , “We have something special for the women who ... season. Moreover, our new collections of 2015 dresses have ... now at greatly discounted prices. Visit our website now ...
Breaking Medicine News(10 mins):Health News:Tons of New-in Winter Sweet 16 Dresses from Weddingshe Online Now 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 3Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 4Health News:VogueQueen Big Sale Online For The Coming 2015 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 4Health News:AngelWeddingDress Has Introduced Its Special Offer For The Coming Christmas 2
... ANGELES, Oct. 3 Pink tags will be ... the supermarket chain partners,with vendors and suppliers to ... Throughout the month, pink tags can be found ... identify participating products,customers can purchase to support breast ...
... Interested in Stopping their Periods, But Unsure,About Medical Implications, ... of,women in a national survey say that they are ... aren,t sure if it,s safe. Yet when,physicians are polled, ... menstruation is, in fact, medically safe and,acceptable. The survey ...
... than the two thirds of the women in a ... their menstrual periods but many of them arent sure ... percent say that continuous oral contraceptive therapy to suppress ... survey results were presented by Kurt Barnhart MD, MSCE ...
... QUINCY, Mass., Oct. 3 The Stop & Shop Supermarket,Company, ... $75,000 to,Susan G. Komen for the Cure with the Pink ... Month," said Stop & Shop/Giant,Consumer Advisor Andrea Astrachan, "and by ... Giant, customers can support the fight against,breast cancer and help ...
... Inverness Medical,Innovations (Amex: IMA ) today announced ... both core laboratory and point of care,diagnostic testing products ... Inverness will pay an earn out up to a ... had,revenues of approximately $29.5m in 2006 and has been ...
... Workers in PA, MI, IL, FL, OH, MD, WI, WA Join Forces in, ... Equity ... Buyout, WASHINGTON, Oct. 3 ... union today,is launching a multi-state grassroots campaign calling on global buyout,giant the Carlyle ...
Cached Medicine News:Health News:Ralphs 'Pink Tag' Campaign to Raise $170,000 for Breast Cancer Awareness in October 2Health News:Safe to Stop the Flow?: Differing Attitudes Found Between Women and Doctors Concerning Menstrual Suppression 2Health News:Safe to Stop the Flow?: Differing Attitudes Found Between Women and Doctors Concerning Menstrual Suppression 3Health News:Differing attitudes found between women and doctors concerning menstrual suppression 2Health News:Stop & Shop and Giant Food Join General Mills in Pink for the Cure 2Health News:Inverness Medical Innovations Acquires Bio-Stat Healthcare Group 2Health News:SEIU Launches Multi-State Grassroots Campaign Calling on the Carlyle Group to Put Care Above Profits in Buyout of Nation's Largest Nursing Home Chain 2
... The TL-100 uses technology that takes ... by automatically detecting and reading them. It ... recording the results, mark lenses as you ... contact lenses. Easy to use, the TL-100 ...
... The Kowa RC-XV3 camera is ... The automatic exposure system, ... sensitivity, the 2.5~300ws watt indication ... handling are the basic features ...
FF 450plus fundus camera for 35mm photography. Upgradeable basic instrument for brilliant image quality....
The new TRC-NW6 non-mydriatic retinal camera is the ideal instrument for the growing market in telemedicine and diabetic screening....
Medicine Products: